ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.23% | 10.17% | 18.71% | 22.45% | -50.28% |
| Total Depreciation and Amortization | -5.96% | -7.40% | -1.82% | -6.09% | 41.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.55% | -2.22% | -22.44% | -28.85% | 99.25% |
| Change in Net Operating Assets | -146.13% | 84.68% | 105.42% | 97.56% | 164.81% |
| Cash from Operations | -32.89% | 31.65% | 41.68% | 36.00% | 46.49% |
| Capital Expenditure | 95.87% | 95.43% | 95.53% | 83.59% | 34.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.99% | 0.99% | 1,413.75% | 5,868.72% | -- |
| Cash from Investing | 17.24% | 18.97% | -31.42% | -21.46% | -65.89% |
| Total Debt Issued | 1,477.57% | 2,140.25% | -60.36% | -73.17% | -97.03% |
| Total Debt Repaid | 90.65% | -118.06% | 34.82% | 25.92% | 14.53% |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,513.24% | 1,090.26% | -47.40% | -66.42% | -96.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.57% | 98.40% | -437.66% | -155.90% | -196.71% |